Cargando…

PB2585: IS THROMBOCYTOPENIA WITH INCREASED IMMATURE PLATELET FRACTION [IPF] IN ICU PATIENTS,A BAD PROGNOSIS?

Detalles Bibliográficos
Autores principales:	Lourenco, Enna Maria, Jakhi, Mr Amit, Nirmal, Mr Thomas, Pandey, Mr Anurag, Vp, Dr Antia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428997/ http://dx.doi.org/10.1097/01.HS9.0000977032.30929.c1

Ejemplares similares

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
por: Kapsouli, F., et al.
Publicado: (2022)

PB2303: THROMBOCYTOPENIA IN COVID-19 PATIENTS ON ECMO SUPPORT
por: Jones, C., et al.
Publicado: (2022)

PB2685: QUALITY OF LIFE IN INDIAN ADULTS WITH IMMUNE THROMBOCYTOPENIA
por: Bhat, Vivek, et al.
Publicado: (2023)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

PB2301: PEDIATRIC IMMUNE THROMBOCYTOPENIA; A GLANCE AT PATIENTS AND CURRENT THERAPEUTIC CHALLENGES
por: Al-Jadiry, M., et al.
Publicado: (2022)

PB2066: SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED AMEGAKARYOCYTIC THROMBOCYTOPENIA AND SUBSEQUENT APLASTIC ANEMIA
por: Seong, Gyuhee, et al.
Publicado: (2023)

PB2194: ISCHEMIC STROKE IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pérez Raya, M., et al.
Publicado: (2022)

PB2294: CHEMOTHERAPY INDUCED THROMBOCYTOPENIA AND ITS ASSOCITAION WITH COAGULOPATHY; A SINGLE CENTRE EXPERIENCE
por: ANWAR, N., et al.
Publicado: (2022)

PB2613: PREDICTIVE MODEL TO EVALUATE THE RISK OF IMMUNE THROMBOCYTOPENIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
por: Cornudella, Jesus, et al.
Publicado: (2023)

PB2621: TREATMENT OF IMMUNE THROMBOCYTOPENIA WITH HETROMBOPAG—A SINGLE-CENTER RETROSPECTIVE, OBSERVATIONAL STUDY
por: Zhou, Hu, et al.
Publicado: (2023)

PB2616: SYSTEMIC LUPUS ERYTHEMATOSUS RELATED IMMUNE THROMBOCYTOPENIA: A CHARACTERISTIC CLINICAL FENOTIPE
por: Cornudella, Jesus, et al.
Publicado: (2023)

PB2274: A PROGNOSTIC MODEL TO PREDICT MORTALITY IN ICU DEPARTMENT OF HEMATOLOGY CLINIC
por: Luchinin, A., et al.
Publicado: (2022)

PB2299: CLINICAL AND LABORATORY CHARACTERISTICS OF CHILDREN WITH INHERITED THROMBOCYTOPENIA IN A SINGLE EGYPTIAN UNIVERSITY HOSPITAL
por: El Chazli, Y., et al.
Publicado: (2022)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE
por: Sayed, Gamal, et al.
Publicado: (2023)

2585. Changing Epidemiological Profile of Infantile Parechovirus-A3 Infection in Japan
por: Aizawa, Yuta, et al.
Publicado: (2019)

2585. Identification of Risk Factors for Pseudomonas aeruginosa in Patients with Community-Acquired Pneumonia
por: Karajeh, Jenna, et al.
Publicado: (2023)

PB2468: A RETROSPECTIVE STUDY OF ELTROMBOPAG IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Liangming, et al.
Publicado: (2023)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

PB2607: OBESITY IMPAIRS RESPONSE TO FIRST-LINE HIGH-DOSE DEXAMETHASONE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.
por: Feng, Gege, et al.
Publicado: (2023)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
por: 吴, ?.
Publicado: (2022)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

PB2628: EXPERIENCE AT THE GUADALAJARA UNIVERSITY HOSPITAL (SPAIN) IN FETAL AND NEONATAL ALLOINMUNE THROMBOCYTOPENIA (FNAIT) DURING EIGHT YEARS.
por: López, María Irene Nuevo, et al.
Publicado: (2023)

Sepsis: thrombocytopenia is bad, not recovering thrombocytopenia is too bad
por: Faviere, W, et al.
Publicado: (2011)

PB2315: EFFICACY AND SAFETY OF TWO DIFFERENT LOW-DOSE RITUXIMAB REGIMENS FOR CHINESE CHILDREN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
por: Zhu, X.
Publicado: (2022)

PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)
por: Tsykunova, G., et al.
Publicado: (2022)

PB2604: THE ROLE OF THE GUT MICROBIOTA IN MEDIATING BONE MARROW MESENCHYMAL STEM CELLS DEFICIENCY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN PREGNANCY
por: Chen, Qi, et al.
Publicado: (2023)

PB2302: HEPARIN-INDUCED THROMBOCYTOPENIA ANTIBODIES CAN MAINTAIN PLATELET-ACTIVATING PROPERTIES AFTER TWO SESSIONS OF THERAPEUTIC PLASMA EXCHANGE
por: Gkalea, V., et al.
Publicado: (2022)

PB2631: CLINICAL FEATURES, TREATMENTS AND OUTCOMES OF PRIMARY IMMUNE THROMBOCYTOPENIA IN ADULTS: A SINGLE CENTER RETROSPECTIVE STUDY FROM TUNISIA.
por: Bnouni, Yasmine, et al.
Publicado: (2023)

PB1924: ARE WE TAKING ADVANTAGE OF THERAPEUTIC OPTIONS IN MYELODYSPLASTIC SYNDROME?-REAL WORLD DATA FROM HUNGARY
por: Miltényi, Z., et al.
Publicado: (2022)

PB2300: COMPLEMENT ACTIVATION NEGATIVELY AFFECTS THE PLATELET RESPONSE TO THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE COHORT STUDY
por: Åkesson, A., et al.
Publicado: (2022)

PB2425: EFFICACY AND SAFETY OF COMBINED THERAPY OF RECOMBINANT HUMAN THROMBOPOIETIN AND ELTROMBOPAG FOR TREATMENT OF PERSISTENT THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pan, Pan, et al.
Publicado: (2023)

PB2308: QUALITY OF LIFE AND CLINICAL OUTCOMES IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ROMIPLOSTIM IN A REAL-WORLD SETTING
por: Ionova, T., et al.
Publicado: (2022)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

PB1968: IMPACTS ON OUTCOMES AND A PREDICTIVE MODEL OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL NILOTINIB-THERAPY
por: LI, Ziyu, et al.
Publicado: (2023)

PB2614: MISDIAGNOSIS OF PRIMARY IMMUNE THROMBOCYTOPENIA IN THE COMMUNITY SETTING AND ITS ASSOCIATION WITH INHERITED PLATELET DISORDERS: REPORTING NEW VARIANTS OF INHERITED PLATELET DISORDERS
por: Lara-Martinez, Hugo, et al.
Publicado: (2023)

Quetiapine in prolonged ICU delirium
por: Kasliwal, MR, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_tgae20751j6kcnmp7to9t6iuoo